Assessing the function of genetic variants in candidate gene association studies

[1]  Francisco E. Baralle,et al.  Genomic variants in exons and introns: identifying the splicing spoilers , 2004, Nature Reviews Genetics.

[2]  Matthew B Schabath,et al.  An Evolutionary Perspective on Single-Nucleotide Polymorphism Screening in Molecular Cancer Epidemiology , 2004, Cancer Research.

[3]  E. Schuetz.  Lessons from the CYP3A4 promoter. , 2004, Molecular pharmacology.

[4]  Zbigniew Michalewicz,et al.  An Evolutionary Approach , 2004 .

[5]  Yoshihide Hayashizaki,et al.  EICO (Expression-based Imprint Candidate Organizer): finding disease-related imprinted genes , 2004, Nucleic Acids Res..

[6]  Stacy T. Knutson,et al.  Prediction of deleterious functional effects of amino acid mutations using a library of structure‐based function descriptors , 2003, Proteins.

[7]  David R. Westhead,et al.  A comparative study of machine-learning methods to predict the effects of single nucleotide polymorphisms on protein function , 2003, Bioinform..

[8]  John Moult,et al.  Three‐dimensional structural location and molecular functional effects of missense SNPs in the T cell receptor Vβ domain , 2003, Proteins.

[9]  N. Plant,et al.  Transcriptional regulation of cytochrome P4503A4 gene expression: effects of inherited mutations in the 5′-flanking region , 2003, Xenobiotica; the fate of foreign compounds in biological systems.

[10]  R. Kim,et al.  Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. , 2003, Pharmacogenetics.

[11]  John M. Hancock,et al.  A phylogenetic approach to assessing the significance of missense mutations in disease genes , 2003, Human mutation.

[12]  Steven Henikoff,et al.  SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..

[13]  J. Stephens,et al.  SNP and haplotype variation in the human genome. , 2003, Mutation research.

[14]  J. Knight,et al.  Functional implications of genetic variation in non-coding DNA for disease susceptibility and gene regulation. , 2003, Clinical science.

[15]  Peter K Rogan,et al.  Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations. , 2003, Pharmacogenetics.

[16]  B. Green,et al.  The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  Dominic P. Kwiatkowski,et al.  In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading , 2003, Nature Genetics.

[18]  M. D. Adams.  ENU mutagenesis for pharma. , 2003, Drug discovery today.

[19]  D. Botstein,et al.  Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease , 2003, Nature Genetics.

[20]  Julie A Schneider,et al.  DNA variability of human genes , 2003, Mechanisms of Ageing and Development.

[21]  E. Lander,et al.  Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease , 2003, Nature Genetics.

[22]  J. Potter,et al.  Understanding missense mutations in the BRCA1 gene: An evolutionary approach , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Rebbeck,et al.  Increased transcriptional activity of the CYP3A4*1B promoter variant , 2003, Environmental and molecular mutagenesis.

[24]  M. Shriver,et al.  Interrogating a high-density SNP map for signatures of natural selection. , 2002, Genome research.

[25]  Milan Mrksich,et al.  Protein chips: from concept to practice. , 2002, Trends in biotechnology.

[26]  T. Rebbeck,et al.  Ethnic Differences in the Frequency of Prostate Cancer Susceptibility Alleles at SRD5A2 and CYP3A4 , 2002, Human Heredity.

[27]  David Glick,et al.  Defects in pre-mRNA processing as causes of and predisposition to diseases. , 2002, DNA and cell biology.

[28]  Christopher T. Saunders,et al.  Evaluation of structural and evolutionary contributions to deleterious mutation prediction. , 2002, Journal of molecular biology.

[29]  P. Bork,et al.  Human non-synonymous SNPs: server and survey. , 2002, Nucleic acids research.

[30]  G. Giles,et al.  The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. , 2002, Pharmacogenetics.

[31]  Ann Daly,et al.  Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. , 2002, Pharmacogenetics.

[32]  S. Henikoff,et al.  Accounting for human polymorphisms predicted to affect protein function. , 2002, Genome research.

[33]  M. Orozco,et al.  Characterization of disease-associated single amino acid polymorphisms in terms of sequence and structure properties. , 2002, Journal of molecular biology.

[34]  J. Ott,et al.  Trimming, weighting, and grouping SNPs in human case-control association studies. , 2001, Genome research.

[35]  S. Narod,et al.  CYP gene polymorphisms and early menarche. , 2001, Molecular genetics and metabolism.

[36]  M. Miller,et al.  Understanding human disease mutations through the use of interspecific genetic variation. , 2001, Human molecular genetics.

[37]  Justin C. Fay,et al.  Positive and negative selection on the human genome. , 2001, Genetics.

[38]  G. An,et al.  Gene tagging in rice: a high throughput system for functional genomics. , 2001, Plant science : an international journal of experimental plant biology.

[39]  S. Henikoff,et al.  Predicting deleterious amino acid substitutions. , 2001, Genome research.

[40]  J. Moult,et al.  SNPs, protein structure, and disease , 2001, Human mutation.

[41]  D. Chasman,et al.  Predicting the functional consequences of non-synonymous single nucleotide polymorphisms: structure-based assessment of amino acid variation. , 2001, Journal of molecular biology.

[42]  Warren C. Lathe,et al.  Prediction of deleterious human alleles. , 2001, Human molecular genetics.

[43]  M. Daly,et al.  A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms , 2001, Nature.

[44]  S. Narod,et al.  Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. , 2001, Molecular genetics and metabolism.

[45]  N. Schork,et al.  Single nucleotide polymorphisms and the future of genetic epidemiology , 2000, Clinical genetics.

[46]  Francesco Cecconi,et al.  Gene trap: a way to identify novel genes and unravel their biological function , 2000, FEBS letters.

[47]  P. Bork,et al.  Towards a structural basis of human non-synonymous single nucleotide polymorphisms. , 2000, Trends in genetics : TIG.

[48]  T. Rebbeck.  Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4 , 1999 .

[49]  M. Cargill.  Characterization of single-nucleotide polymorphisms in coding regions of human genes , 1999, Nature Genetics.

[50]  J. Witte,et al.  Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[51]  K. Shimokata,et al.  Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. , 1999, Journal of the National Cancer Institute.

[52]  M. Ingelman-Sundberg,et al.  Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. , 1999, Biochemical and biophysical research communications.

[53]  Walker,et al.  RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 , 1999, Journal of the National Cancer Institute.

[54]  M. Ehm,et al.  Detecting marker-disease association by testing for Hardy-Weinberg disequilibrium at a marker locus. , 1998, American journal of human genetics.

[55]  P. Nowell,et al.  Association of CYP3A4 genotype with treatment-related leukemia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[56]  T. Rebbeck,et al.  More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. , 2000, Journal of the National Cancer Institute.

[57]  M. C. Ellis,et al.  A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis , 1996, Nature Genetics.

[58]  A. Li,et al.  Substrates of human hepatic cytochrome P450 3A4. , 1995, Toxicology.

[59]  S. Tagawa,et al.  Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. , 1993, European journal of biochemistry.

[60]  Dominic P. Searson,et al.  An evolutionary approach , 1993 .

[61]  Max F. Perutz,et al.  Structure and function of haemoglobin: I. A tentative atomic model of horse oxyhaemoglobin , 1965 .